Context-specific functions of chromatin remodellers in development and disease.

Flaus, A. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 34, 2887–2905 (2006).

pubmed: 16738128 pmcid: 1474054 doi: 10.1093/nar/gkl295

Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C. & Chan, H. M. Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 36, 936–950 (2020).

pubmed: 32873422 doi: 10.1016/j.tig.2020.07.011

Hodges, C., Kirkland, J. G. & Crabtree, G. R. The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb. Perspect. Med. 6, a026930 (2016).

pubmed: 27413115 pmcid: 4968166 doi: 10.1101/cshperspect.a026930

Pulice, J. L. & Kadoch, C. Composition and function of mammalian SWI/SNF chromatin remodeling complexes in human disease. Cold Spring Harb. Symp. Quant. Biol. 81, 53–60 (2016).

pubmed: 28408647 doi: 10.1101/sqb.2016.81.031021

Bracken, A. P., Brien, G. L. & Verrijzer, C. P. Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. Genes. Dev. 33, 936–959 (2019).

pubmed: 31123059 pmcid: 6672049 doi: 10.1101/gad.326066.119

Ho, P. J., Lloyd, S. M. & Bao, X. Unwinding chromatin at the right places: how BAF is targeted to specific genomic locations during development. Development 146, dev178780 (2019).

pubmed: 31570369 pmcid: 6803370 doi: 10.1242/dev.178780

Alendar, A. & Berns, A. Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease. Genes Dev. 35, 1403–1430 (2021).

pubmed: 34725129 pmcid: 8559672 doi: 10.1101/gad.348897.121

Clapier, C. R. Sophisticated conversations between chromatin and chromatin remodelers, and dissonances in cancer. Int. J. Mol. Sci. 22, ijms22115578 (2021).

doi: 10.3390/ijms22115578

Hota, S. K. & Bruneau, B. G. ATP-dependent chromatin remodeling during mammalian development. Development 143, 2882–2897 (2016). Hota and Bruneau comprehensively review genetic and functional studies showing the unique roles of chromatin remodellers during mammalian development.

pubmed: 27531948 pmcid: 5004879 doi: 10.1242/dev.128892

Sundaramoorthy, R. & Owen-Hughes, T. Chromatin remodelling comes into focus. F1000Res 9, https://doi.org/10.12688/f1000research.21933.1 (2020).

Hirschhorn, J. N., Brown, S. A., Clark, C. D. & Winston, F. Evidence that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chromatin structure. Genes. Dev. 6, 2288–2298 (1992).

pubmed: 1459453 doi: 10.1101/gad.6.12a.2288

Sternberg, P. W., Stern, M. J., Clark, I. & Herskowitz, I. Activation of the yeast HO gene by release from multiple negative controls. Cell 48, 567–577 (1987).

pubmed: 3545494 doi: 10.1016/0092-8674(87)90235-2

Nasmyth, K., Stillman, D. & Kipling, D. Both positive and negative regulators of HO transcription are required for mother-cell-specific mating-type switching in yeast. Cell 48, 579–587 (1987).

pubmed: 3028642 doi: 10.1016/0092-8674(87)90236-4

Mizuguchi, G. et al. ATP-driven exchange of histone H2AZ variant catalyzed by SWR1 chromatin remodeling complex. Science 303, 343–348 (2004).

pubmed: 14645854 doi: 10.1126/science.1090701

Hota, S. K. et al. Nucleosome mobilization by ISW2 requires the concerted action of the ATPase and SLIDE domains. Nat. Struct. Mol. Biol. 20, 222–229 (2013).

pubmed: 23334290 pmcid: 3565048 doi: 10.1038/nsmb.2486

Hamiche, A., Sandaltzopoulos, R., Gdula, D. A. & Wu, C. ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF. Cell 97, 833–842 (1999).

pubmed: 10399912 doi: 10.1016/S0092-8674(00)80796-5

Langst, G., Bonte, E. J., Corona, D. F. & Becker, P. B. Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer. Cell 97, 843–852 (1999).

pubmed: 10399913 doi: 10.1016/S0092-8674(00)80797-7

Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E. & Green, M. R. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 370, 477–481 (1994).

pubmed: 8047169 doi: 10.1038/370477a0

Ayala, R. et al. Structure and regulation of the human INO80-nucleosome complex. Nature 556, 391–395 (2018).

pubmed: 29643506 pmcid: 5937682 doi: 10.1038/s41586-018-0021-6

Narlikar, G. J., Sundaramoorthy, R. & Owen-Hughes, T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 154, 490–503 (2013). This is a clear and concise review of the basic biochemical mechanisms of nucleosome remodelling.

pubmed: 23911317 pmcid: 3781322 doi: 10.1016/j.cell.2013.07.011

Deuring, R. et al. The ISWI chromatin-remodeling protein is required for gene expression and the maintenance of higher order chromatin structure in vivo. Mol. Cell 5, 355–365 (2000).

pubmed: 10882076 doi: 10.1016/S1097-2765(00)80430-X

Längst, G. & Becker, P. B. Nucleosome mobilization and positioning by ISWI-containing chromatin-remodeling factors. J. Cell Sci. 114, 2561–2568 (2001).

pubmed: 11683384 doi: 10.1242/jcs.114.14.2561

Drane, P., Ouararhni, K., Depaux, A., Shuaib, M. & Hamiche, A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 24, 1253–1265 (2010).

pubmed: 20504901 pmcid: 2885661 doi: 10.1101/gad.566910

Lewis, P. W., Elsaesser, S. J., Noh, K. M., Stadler, S. C. & Allis, C. D. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc. Natl Acad. Sci. USA 107, 14075–14080 (2010).

pubmed: 20651253 pmcid: 2922592 doi: 10.1073/pnas.1008850107

Dyer, M. A., Qadeer, Z. A., Valle-Garcia, D. & Bernstein, E. ATRX and DAXX: mechanisms and mutations. Cold Spring Harb. Perspect. Med. 7, a026567 (2017).

pubmed: 28062559 pmcid: 5334245 doi: 10.1101/cshperspect.a026567

Ni, K. et al. LSH mediates gene repression through macroH2A deposition. Nat. Commun. 11, 5647 (2020).

pubmed: 33159050 pmcid: 7648012 doi: 10.1038/s41467-020-19159-0

Kadoch, C. et al. Dynamics of BAF–Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat. Genet. 49, 213–222 (2017).

pubmed: 27941796 doi: 10.1038/ng.3734

Stanton, B. Z. et al. Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat. Genet. 49, 282–288 (2017).

pubmed: 27941795 doi: 10.1038/ng.3735

Clapier, C. R. & Cairns, B. R. Regulation of ISWI involves inhibitory modules antagonized by nucleosomal epitopes. Nature 492, 280–284 (2012).

pubmed: 23143334 pmcid: 3631562 doi: 10.1038/nature11625

Wu, J. I., Lessard, J. & Crabtree, G. R. Understanding the words of chromatin regulation. Cell 136, 200–206 (2009).

pubmed: 19167321 pmcid: 2770578 doi: 10.1016/j.cell.2009.01.009

Mashtalir, N. et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell 175, 1272–1288 e1220 (2018).

pubmed: 30343899 pmcid: 6791824 doi: 10.1016/j.cell.2018.09.032

Erdel, F. & Rippe, K. Chromatin remodelling in mammalian cells by ISWI-type complexes—where, when and why? FEBS J. 278, 3608–3618 (2011).

pubmed: 21810179 doi: 10.1111/j.1742-4658.2011.08282.x

Wang, W. et al. Diversity and specialization of mammalian SWI/SNF complexes. Genes. Dev. 10, 2117–2130 (1996).

pubmed: 8804307 doi: 10.1101/gad.10.17.2117

Wang, W. et al. Purification and biochemical heterogeneity of the mammalian SWI–SNF complex. EMBO J. 15, 5370–5382 (1996).

pubmed: 8895581 pmcid: 452280 doi: 10.1002/j.1460-2075.1996.tb00921.x

Ren, J. et al. Single-cell transcriptomes and whole-brain projections of serotonin neurons in the mouse dorsal and median raphe nuclei. eLife 8, e49424 (2019).

pubmed: 31647409 pmcid: 6812963 doi: 10.7554/eLife.49424

Chang, C. Y. et al. Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma. Mol. Cell 81, 4964–4978 e4968 (2021).

pubmed: 34687603 pmcid: 8761479 doi: 10.1016/j.molcel.2021.10.005

Biggin, M. D. Animal transcription networks as highly connected, quantitative continua. Dev. Cell 21, 611–626 (2011).

pubmed: 22014521 doi: 10.1016/j.devcel.2011.09.008

Fulton, S. L. et al. Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome. Nat. Commun. 13, 6384 (2022).

pubmed: 36289231 pmcid: 9606253 doi: 10.1038/s41467-022-34200-0

Braun, S. M. G. et al. BAF subunit switching regulates chromatin accessibility to control cell cycle exit in the developing mammalian cortex. Genes. Dev. 35, 335–353 (2021).

pubmed: 33602870 pmcid: 7919417 doi: 10.1101/gad.342345.120

Lessard, J. et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 55, 201–215 (2007). Lessard and colleagues describe a neuron-specific remodelling complex (neuronal BAF or nBAF) with subunits expressed only in the nervous system.

pubmed: 17640523 pmcid: 2674110 doi: 10.1016/j.neuron.2007.06.019

Goodman, J. V. & Bonni, A. Regulation of neuronal connectivity in the mammalian brain by chromatin remodeling. Curr. Opin. Neurobiol. 59, 59–68 (2019).

pubmed: 31146125 pmcid: 6879819 doi: 10.1016/j.conb.2019.04.010

Nitarska, J. et al. A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. Cell Rep. 17, 1683–1698 (2016).

pubmed: 27806305 pmcid: 5149529 doi: 10.1016/j.celrep.2016.10.022

Yoo, A. S., Staahl, B. T., Chen, L. & Crabtree, G. R. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 460, 642–646 (2009).

pubmed: 19561591 pmcid: 2921580 doi: 10.1038/nature08139

Takeuchi, J. K. & Bruneau, B. G. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 459, 708–711 (2009). These two studies defined switches in BAF complex subunit composition that are instructive for maturation of neurons (Yoo et al., 2009) or the cardiomyocytes (Takeuchi et al., 2009), and the groups have continued to study the cell-type-specific remodeller complexes.

pubmed: 19396158 pmcid: 2728356 doi: 10.1038/nature08039

Lim, H. Y. G. et al. Keratins are asymmetrically inherited fate determinants in the mammalian embryo. Nature 585, 404–409 (2020).

pubmed: 32848249 doi: 10.1038/s41586-020-2647-4

Ho, L. et al. An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc. Natl Acad. Sci. USA 106, 5181–5186 (2009).

pubmed: 19279220 pmcid: 2654396 doi: 10.1073/pnas.0812889106

Cairns, B. R. et al. RSC, an essential, abundant chromatin-remodeling complex. Cell 87, 1249–1260 (1996).

pubmed: 8980231 doi: 10.1016/S0092-8674(00)81820-6

Laurent, B. C., Yang, X. & Carlson, M. An essential Saccharomyces cerevisiae gene homologous to SNF2 encodes a helicase-related protein in a new family. Mol. Cell Biol. 12, 1893–1902 (1992).

pubmed: 1549132 pmcid: 369633

Tsuchiya, E. et al. The Saccharomyces cerevisiae NPS1 gene, a novel CDC gene which encodes a 160 kDa nuclear protein involved in G2 phase control. EMBO J. 11, 4017–4026 (1992).

pubmed: 1396591 pmcid: 556912 doi: 10.1002/j.1460-2075.1992.tb05495.x

Tsukiyama, T., Palmer, J., Landel, C. C., Shiloach, J. & Wu, C. Characterization of the imitation switch subfamily of ATP-dependent chromatin-remodeling factors in Saccharomyces cerevisiae. Genes. Dev. 13, 686–697 (1999).

pubmed: 10090725 pmcid: 316555 doi: 10.1101/gad.13.6.686

Alén, C. et al. A role for chromatin remodeling in transcriptional termination by RNA polymerase II. Mol. Cell 10, 1441–1452 (2002).

pubmed: 12504018 doi: 10.1016/S1097-2765(02)00778-5

Gkikopoulos, T. et al. A role for Snf2-related nucleosome-spacing enzymes in genome-wide nucleosome organization. Science 333, 1758–1760 (2011).

pubmed: 21940898 pmcid: 3428865 doi: 10.1126/science.1206097

Kubik, S. et al. Opposing chromatin remodelers control transcription initiation frequency and start site selection. Nat. Struct. Mol. Biol. 26, 744–754 (2019).

pubmed: 31384063 doi: 10.1038/s41594-019-0273-3

Krietenstein, N. et al. Genomic nucleosome organization reconstituted with pure proteins. Cell 167, e712 (2016).

doi: 10.1016/j.cell.2016.09.045

Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).

pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7

Rice, A. M. & McLysaght, A. Dosage sensitivity is a major determinant of human copy number variant pathogenicity. Nat. Commun. 8, 14366 (2017).

pubmed: 28176757 pmcid: 5309798 doi: 10.1038/ncomms14366

Firth, H. V. et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using Ensembl resources. Am. J. Hum. Genet. 84, 524–533 (2009).

pubmed: 19344873 pmcid: 2667985 doi: 10.1016/j.ajhg.2009.03.010

Valencia, A. M. et al. Landscape of mSWI/SNF chromatin remodeling complex perturbations in neurodevelopmental disorders. Nat. Genet. 55, 1400–1412 (2023).

pubmed: 37500730 pmcid: 10412456 doi: 10.1038/s41588-023-01451-6

Morrill, S. A. & Amon, A. Why haploinsufficiency persists. Proc. Natl Acad. Sci. USA 116, 11866–11871 (2019). Morill and Amon provide an insightful perspective on how genetic dosage and haploinsufficiency contribute to cellular fitness.

pubmed: 31142641 pmcid: 6575174 doi: 10.1073/pnas.1900437116

Wenderski, W. et al. Loss of the neural-specific BAF subunit ACTL6B relieves repression of early response genes and causes recessive autism. Proc. Natl Acad. Sci. USA 117, 10055–10066 (2020). The authors identified recessive missense variants in a neuron-specific subunit of the BAF complex in individuals with autism spectrum disorder, and mapped their biochemical contributions to autism-spectrum-disorder-related phenotypes in flies, human organoids and mouse models, finding that these mutations produce specific defects in social behaviour and neuronal-activity-dependent responses.

pubmed: 32312822 pmcid: 7211998 doi: 10.1073/pnas.1908238117

Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).

pubmed: 27535533 pmcid: 5018207 doi: 10.1038/nature19057

Minikel, E. V. et al. Evaluating drug targets through human loss-of-function genetic variation. Nature 581, 459–464 (2020).

pubmed: 32461653 pmcid: 7272226 doi: 10.1038/s41586-020-2267-z

The Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223–228 (2015).

doi: 10.1038/nature14135

Kennison, J. A. & Tamkun, J. W. Dosage-dependent modifiers of Polycomb and Antennapedia mutations in Drosophila. Proc. Natl Acad. Sci. USA 85, 8136–8140 (1988). In this study, Kennison and Tamkun identified the ATPase Brahma (part of the BAF complex) and its role in opposing Polycomb complexes; the opposition between Polycomb and BAF complexes is a crucial underlying mechanism that has been observed in many human malignancies and developmental disorders.

pubmed: 3141923 pmcid: 282375 doi: 10.1073/pnas.85.21.8136

Deal, R. B., Henikoff, J. G. & Henikoff, S. Genome-wide kinetics of nucleosome turnover determined by metabolic labeling of histones. Science 328, 1161–1164 (2010). Deal, Henikoff and Henikoff develop a chemical biological method to measure rates of nucleosome turnover and find that turnover occurs faster than a cell cycle across most of the genome, implying that nucleosome remodelling itself can regulate active or repressive gene expression states simply by modulating local DNA accessibility.

pubmed: 20508129 pmcid: 2879085 doi: 10.1126/science.1186777

Lai, B. et al. Principles of nucleosome organization revealed by single-cell micrococcal nuclease sequencing. Nature 562, 281–285 (2018).

pubmed: 30258225 pmcid: 8353605 doi: 10.1038/s41586-018-0567-3

Yildirim, O. et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147, 1498–1510 (2011).

pubmed: 22196727 pmcid: 3252821 doi: 10.1016/j.cell.2011.11.054

Narlikar, G. J., Fan, H.-Y. & Kingston, R. E. Cooperation between complexes that regulate chromatin structure and transcription. Cell 108, 475–487 (2002).

pubmed: 11909519 doi: 10.1016/S0092-8674(02)00654-2

Cirillo, L. A. et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 9, 279–289 (2002).

pubmed: 11864602 doi: 10.1016/S1097-2765(02)00459-8

Soufi, A. et al. Pioneer transcription factors target partial DNA motifs on nucleosomes to initiate reprogramming. Cell 161, 555–568 (2015).

pubmed: 25892221 pmcid: 4409934 doi: 10.1016/j.cell.2015.03.017

Barozzi, I. et al. Coregulation of transcription factor binding and nucleosome occupancy through DNA features of mammalian enhancers. Mol. Cell 54, 844–857 (2014).

pubmed: 24813947 pmcid: 4048654 doi: 10.1016/j.molcel.2014.04.006

Miller, E. L. et al. TOP2 synergizes with BAF chromatin remodeling for both resolution and formation of facultative heterochromatin. Nat. Struct. Mol. Biol. 24, 344–352 (2017).

pubmed: 28250416 pmcid: 5395302 doi: 10.1038/nsmb.3384

King, H. W. & Klose, R. J. The pioneer factor OCT4 requires the chromatin remodeller BRG1 to support gene regulatory element function in mouse embryonic stem cells. eLife 6, e22631 (2017).

pubmed: 28287392 pmcid: 5400504 doi: 10.7554/eLife.22631

Friman, E. T. et al. Dynamic regulation of chromatin accessibility by pluripotency transcription factors across the cell cycle. eLife 8, e50087 (2019).

pubmed: 31794382 pmcid: 6890464 doi: 10.7554/eLife.50087

Xiao, L. et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature 601, 434–439 (2021).

pubmed: 34937944 pmcid: 8770127 doi: 10.1038/s41586-021-04246-z

Wang, W. et al. Architectural DNA binding by a high-mobility-group/kinesin-like subunit in mammalian SWI/SNF-related complexes. Proc. Natl Acad. Sci. USA 95, 492–498 (1998).

pubmed: 9435219 pmcid: 18447 doi: 10.1073/pnas.95.2.492

Smith, M. J. et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295–298 (2013).

pubmed: 23377182 doi: 10.1038/ng.2552

Barisic, D., Stadler, M. B., Iurlaro, M. & Schubeler, D. Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature 569, 136–140 (2019). Barisic and colleagues use functional genomic and epigenomic analyses to identify the unique contributions of different remodellers to the binding of different transcription factors in mouse embryonic stem cells.

pubmed: 30996347 pmcid: 6522387 doi: 10.1038/s41586-019-1115-5

Swinstead, E. E., Paakinaho, V., Presman, D. M. & Hager, G. L. Pioneer factors and ATP-dependent chromatin remodeling factors interact dynamically: a new perspective. BioEssays 38, 1150–1157 (2016).

pubmed: 27633730 pmcid: 6319265 doi: 10.1002/bies.201600137

Grossman, S. R. et al. Positional specificity of different transcription factor classes within enhancers. Proc. Natl Acad. Sci. USA 115, E7222–E7230 (2018).

pubmed: 29987030 pmcid: 6065035 doi: 10.1073/pnas.1804663115

Kim, J. M. et al. Single-molecule imaging of chromatin remodelers reveals role of ATPase in promoting fast kinetics of target search and dissociation from chromatin. eLife 10, e69387 (2021). Kim and colleagues measure rates of remodeller association with chromatin and find very fast residence times (less than ten seconds), proposing a ‘tug-of-war’ model between many remodellers and other regulators and loci on chromatin.

pubmed: 34313223 pmcid: 8352589 doi: 10.7554/eLife.69387

Erin et al. Steroid receptors reprogram FoxA1 occupancy through dynamic chromatin transitions. Cell 165, 593–605 (2016).

doi: 10.1016/j.cell.2016.02.067

Iurlaro, M. et al. Mammalian SWI/SNF continuously restores local accessibility to chromatin. Nat. Genet. 53, 279–287 (2021).

pubmed: 33558757 doi: 10.1038/s41588-020-00768-w

Schick, S. et al. Acute BAF perturbation causes immediate changes in chromatin accessibility. Nat. Genet. 53, 269–278 (2021).

pubmed: 33558760 pmcid: 7614082 doi: 10.1038/s41588-021-00777-3

Johnson, T. A. et al. Conventional and pioneer modes of glucocorticoid receptor interaction with enhancer chromatin in vivo. Nucleic Acids Res. 46, 203–214 (2018).

pubmed: 29126175 doi: 10.1093/nar/gkx1044

Paun, O. et al. Pioneer factor ASCL1 cooperates with the mSWI/SNF complex at distal regulatory elements to regulate human neural differentiation. Genes. Dev. 37, 218–242 (2023).

pubmed: 36931659 pmcid: 10111863 doi: 10.1101/gad.350269.122

Esch, D. et al. A unique Oct4 interface is crucial for reprogramming to pluripotency. Nat. Cell Biol. 15, 295–301 (2013).

pubmed: 23376973 doi: 10.1038/ncb2680

Takaku, M. et al. GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler. Genome Biol. 17, 36 (2016).

pubmed: 26922637 pmcid: 4769547 doi: 10.1186/s13059-016-0897-0

Zentner, G. E., Tsukiyama, T. & Henikoff, S. ISWI and CHD chromatin remodelers bind promoters but act in gene bodies. PLoS Genet. 9, e1003317 (2013).

pubmed: 23468649 pmcid: 3585014 doi: 10.1371/journal.pgen.1003317

Weber, C. M. et al. mSWI/SNF promotes Polycomb repression both directly and through genome-wide redistribution. Nat. Struct. Mol. Biol. 28, 501–511 (2021).

pubmed: 34117481 pmcid: 8504423 doi: 10.1038/s41594-021-00604-7

Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180, 568–584.e523 (2020).

pubmed: 31981491 pmcid: 7250485 doi: 10.1016/j.cell.2019.12.036

Son, E. Y. & Crabtree, G. R. The role of BAF (mSWI/SNF) complexes in mammalian neural development. Am. J. Med. Genet. C 166, 333–349 (2014).

doi: 10.1002/ajmg.c.31416

Snijders Blok, L. et al. CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. Nat. Commun. 9, 4619 (2018).

pubmed: 30397230 pmcid: 6218476 doi: 10.1038/s41467-018-06014-6

Ronan, J. L., Wu, W. & Crabtree, G. R. From neural development to cognition: unexpected roles for chromatin. Nat. Rev. Genet. 14, 347–359 (2013).

pubmed: 23568486 pmcid: 4010428 doi: 10.1038/nrg3413

Sood, S. et al. CHD8 dosage regulates transcription in pluripotency and early murine neural differentiation. Proc. Natl Acad. Sci. USA 117, 22331–22340 (2020).

pubmed: 32839322 pmcid: 7486765 doi: 10.1073/pnas.1921963117

Breuss, M. W. & Gleeson, J. G. When size matters: CHD8 in autism. Nat. Neurosci. 19, 1430–1432 (2016).

pubmed: 27786184 doi: 10.1038/nn.4431

Durak, O. et al. Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling. Nat. Neurosci. 19, 1477–1488 (2016).

pubmed: 27694995 pmcid: 5386887 doi: 10.1038/nn.4400

Rhee, S. et al. Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nat. Commun. 9, 368 (2018).

pubmed: 29371594 pmcid: 5785521 doi: 10.1038/s41467-017-02796-3

Tuoc, T. C. et al. Chromatin regulation by BAF170 controls cerebral cortical size and thickness. Dev. Cell 25, 256–269 (2013).

pubmed: 23643363 doi: 10.1016/j.devcel.2013.04.005

Goljanek-Whysall, K. et al. myomiR-dependent switching of BAF60 variant incorporation into Brg1 chromatin remodeling complexes during embryo myogenesis. Development 141, 3378–3387 (2014).

pubmed: 25078649 pmcid: 4199139 doi: 10.1242/dev.108787

Saccone, V. et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes. Dev. 28, 841–857 (2014).

pubmed: 24682306 pmcid: 4003277 doi: 10.1101/gad.234468.113

Goodwin, L. R. & Picketts, D. J. The role of ISWI chromatin remodeling complexes in brain development and neurodevelopmental disorders. Mol. Cell Neurosci. 87, 55–64 (2018).

pubmed: 29249292 doi: 10.1016/j.mcn.2017.10.008

Alberini, C. M. & Kandel, E. R. The regulation of transcription in memory consolidation. Cold Spring Harb. Perspect. Biol. 7, a021741 (2014).

pubmed: 25475090 doi: 10.1101/cshperspect.a021741

Kim, B. et al. Neuronal activity-induced BRG1 phosphorylation regulates enhancer activation. Cell Rep. 36, 109357 (2021).

pubmed: 34260936 pmcid: 8315893 doi: 10.1016/j.celrep.2021.109357

Yang, Y. et al. Chromatin remodeling inactivates activity genes and regulates neural coding. Science 353, 300–305 (2016).

pubmed: 27418512 pmcid: 4993111 doi: 10.1126/science.aad4225

Wu, J. I. et al. Regulation of dendritic development by neuron-specific chromatin remodeling complexes. Neuron 56, 94–108 (2007).

pubmed: 17920018 doi: 10.1016/j.neuron.2007.08.021

Aizawa, H. et al. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. Science 303, 197–202 (2004). Aizawa and colleagues discovered that CREST (a subunit of the BAF complex) is required for activity-dependent dendritic outgrowth; these findings initiated further studies by this group and many others to understand the contributions of remodellers to activity-dependent neuronal processes.

pubmed: 14716005 doi: 10.1126/science.1089845

Tea, J. S. & Luo, L. The chromatin remodeling factor Bap55 functions through the TIP60 complex to regulate olfactory projection neuron dendrite targeting. Neural Dev. 6, 5 (2011).

pubmed: 21284845 pmcid: 3038883 doi: 10.1186/1749-8104-6-5

Walsh, J. J. et al. Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD. Neuropsychopharmacology 46, 2000–2010 (2021).

pubmed: 34239048 pmcid: 8429585 doi: 10.1038/s41386-021-01091-6

Valencia, A. M. et al. Recurrent SMARCB1 mutations reveal a nucleosome acidic patch interaction site that potentiates mSWI/SNF complex chromatin remodeling. Cell 179, 1342–1356.e1323 (2019). Valencia and colleagues used hotspot disease mutations in a BAF subunit to elucidate its biochemical interactions with the nucleosome; the study provides a roadmap for how human genetics data can be used for studies of remodeller mechanisms.

pubmed: 31759698 pmcid: 7175411 doi: 10.1016/j.cell.2019.10.044

Mashtalir, N. et al. A structural model of the endogenous human BAF complex informs disease mechanisms. Cell 183, 802–817 e824 (2020).

pubmed: 33053319 pmcid: 7717177 doi: 10.1016/j.cell.2020.09.051

Zhao, K. et al. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell 95, 625–636 (1998).

pubmed: 9845365 doi: 10.1016/S0092-8674(00)81633-5

Riviere, J. B. et al. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. Nat. Genet. 44, 440–444 (2012).

pubmed: 22366783 pmcid: 3677859 doi: 10.1038/ng.1091

Cuvertino, S. et al. ACTB loss-of-function mutations result in a pleiotropic developmental disorder. Am. J. Hum. Genet. 101, 1021–1033 (2017).

pubmed: 29220674 pmcid: 5812896 doi: 10.1016/j.ajhg.2017.11.006

He, S. et al. Structure of nucleosome-bound human BAF complex. Science 367, 875–881 (2020).

pubmed: 32001526 doi: 10.1126/science.aaz9761

Clapier, C. R. et al. Regulation of DNA translocation efficiency within the chromatin remodeler RSC/Sth1 potentiates nucleosome sliding and ejection. Mol. Cell 62, 453–461 (2016).

pubmed: 27153540 pmcid: 5291166 doi: 10.1016/j.molcel.2016.03.032

Xie, X., Jankauskas, R., Mazari, A. M. A., Drou, N. & Percipalle, P. β-actin regulates a heterochromatin landscape essential for optimal induction of neuronal programs during direct reprograming. PLoS Genet. 14, e1007846 (2018).

pubmed: 30557298 pmcid: 6312353 doi: 10.1371/journal.pgen.1007846

Mahmood, S. R. et al. β-actin dependent chromatin remodeling mediates compartment level changes in 3D genome architecture. Nat. Commun. 12, 5240 (2021).

pubmed: 34475390 pmcid: 8413440 doi: 10.1038/s41467-021-25596-2

Gibbons, R. J., Picketts, D. J., Villard, L. & Higgs, D. R. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome). Cell 80, 837–845 (1995).

pubmed: 7697714 doi: 10.1016/0092-8674(95)90287-2

Goldberg, A. D. et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140, 678–691 (2010).

pubmed: 20211137 pmcid: 2885838 doi: 10.1016/j.cell.2010.01.003

Noh, K. M. et al. ATRX tolerates activity-dependent histone H3 methyl/phos switching to maintain repetitive element silencing in neurons. Proc. Natl Acad. Sci. USA 112, 6820–6827 (2015).

pubmed: 25538301 doi: 10.1073/pnas.1411258112

Sachs, P. et al. SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells. Nat. Commun. 10, 1335 (2019).

pubmed: 30902974 pmcid: 6430823 doi: 10.1038/s41467-019-09078-0

Kadoch, C. & Crabtree, G. R. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447 (2015).

pubmed: 26601204 pmcid: 4640607 doi: 10.1126/sciadv.1500447

Dunaief, J. L. et al. The retinoblastoma protein and BRGI form a complex and cooperateto induce cell cycle arrest. Cell 79, 119–130 (1994). This paper describes the first evidence that remodellers can act as tumour suppressors.

pubmed: 7923370 doi: 10.1016/0092-8674(94)90405-7

Wong, A. K. C. et al. BRG1, a component of the SWI–SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60, 6171–6177 (2000).

pubmed: 11085541

Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971).

pubmed: 5279523 pmcid: 389051 doi: 10.1073/pnas.68.4.820

Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998).

pubmed: 9671307 doi: 10.1038/28212

Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74–79 (1999).

pubmed: 9892189

Sevenet, N. et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am. J. Hum. Genet. 65, 1342–1348 (1999).

pubmed: 10521299 pmcid: 1288286 doi: 10.1086/302639

Biegel, J. A. et al. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer 28, 31–37 (2000).

pubmed: 10738300 doi: 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y

Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).

pubmed: 21248752 pmcid: 3030920 doi: 10.1038/nature09639

Sanchez-Vega, F. et al. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell 173, 321–337.e310 (2018).

pubmed: 29625050 pmcid: 6070353 doi: 10.1016/j.cell.2018.03.035

Davoli, T. et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948–962 (2013).

pubmed: 24183448 pmcid: 3891052 doi: 10.1016/j.cell.2013.10.011

Kolla, V., Zhuang, T., Higashi, M., Naraparaju, K. & Brodeur, G. M. Role of CHD5 in human cancers: 10 years later. Cancer Res. 74, 652–658 (2014).

pubmed: 24419087 pmcid: 3965582 doi: 10.1158/0008-5472.CAN-13-3056

Burkhardt, L. et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73, 2795–2805 (2013).

pubmed: 23492366 doi: 10.1158/0008-5472.CAN-12-1342

Graf, M. et al. Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. Nat. Commun. 13, 1544 (2022).

pubmed: 35318328 pmcid: 8941154 doi: 10.1038/s41467-022-29152-4

Wu, J. N. & Roberts, C. W. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 3, 35–43 (2013).

pubmed: 23208470 doi: 10.1158/2159-8290.CD-12-0361

Bultman, S. J. et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27, 460–468 (2008).

pubmed: 17637742 doi: 10.1038/sj.onc.1210664

Wanior, M., Kramer, A., Knapp, S. & Joerger, A. C. Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. Oncogene 40, 3637–3654 (2021).

pubmed: 33941852 pmcid: 8154588 doi: 10.1038/s41388-021-01781-x

Garbarino, J., Eckroate, J., Sundaram, R. K., Jensen, R. B. & Bindra, R. S. Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. Transl. Oncol. 14, 101147 (2021).

pubmed: 34118569 pmcid: 8203843 doi: 10.1016/j.tranon.2021.101147

Hoffman, G. R. et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. USA 111, 3128–3133 (2014).

pubmed: 24520176 pmcid: 3939885 doi: 10.1073/pnas.1316793111

Helming, K. C. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20, 251–254 (2014).

pubmed: 24562383 pmcid: 3954704 doi: 10.1038/nm.3480

Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).

pubmed: 29083409 pmcid: 5709193 doi: 10.1038/ng.3984

Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24, 556–562 (2018).

pubmed: 29736026 pmcid: 6076433 doi: 10.1038/s41591-018-0012-z

Okamura, R. et al. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J. Immunother. Cancer 8, e000438 (2020).

pubmed: 32111729 pmcid: 7057434 doi: 10.1136/jitc-2019-000438

Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018).

pubmed: 29301958 pmcid: 5953516 doi: 10.1126/science.aao1710

Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).

pubmed: 29301960 pmcid: 6035749 doi: 10.1126/science.aan5951

Krishnamurthy, N., Kato, S., Lippman, S. & Kurzrock, R. Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy. J. Immunother. Cancer 10, e004669 (2022).

pmcid: 9442488 doi: 10.1136/jitc-2022-004669

Guo, A. et al. cBAF complex components and MYC cooperate early in CD8

pubmed: 35732731 pmcid: 9623036 doi: 10.1038/s41586-022-04849-0

Nakayama, R. T. et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat. Genet. 49, 1613–1623 (2017).

pubmed: 28945250 pmcid: 5803080 doi: 10.1038/ng.3958

Wang, X. et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat. Genet. 49, 289–295 (2017).

pubmed: 27941797 doi: 10.1038/ng.3746

Liu, W. et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 31, 3939–3948 (2012).

pubmed: 22139082 doi: 10.1038/onc.2011.554

Augello, M. A. et al. CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell 35, 603–617.e608 (2019).

pubmed: 30930119 pmcid: 6467783 doi: 10.1016/j.ccell.2019.03.001

Egan, C. M. et al. CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and Polycomb gene repression. Dev. Cell 26, 223–236 (2013).

pubmed: 23948251 doi: 10.1016/j.devcel.2013.07.008

Dykhuizen, E. C. et al. BAF complexes facilitate decatenation of DNA by topoisomerase II α. Nature 497, 624–627 (2013).

pubmed: 23698369 pmcid: 3668793 doi: 10.1038/nature12146

Fillmore, C. M. et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 563, E27 (2015).

doi: 10.1038/s41586-018-0580-6

Seoane, J. A., Kirkland, J. G., Caswell-Jin, J. L., Crabtree, G. R. & Curtis, C. Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nat. Med. 25, 1721–1727 (2019).

pubmed: 31700186 pmcid: 7220800 doi: 10.1038/s41591-019-0638-5

Kakarougkas, A. et al. Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol. Cell 55, 723–732 (2014).

pubmed: 25066234 pmcid: 4157577 doi: 10.1016/j.molcel.2014.06.028

Chan, C. S. et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct α-cell signature subgroup. Nat. Commun. 9, 4158 (2018).

pubmed: 30315258 pmcid: 6185985 doi: 10.1038/s41467-018-06498-2

Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425 (2011).

pubmed: 21719641 pmcid: 3174141 doi: 10.1126/science.1207313

Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226–231 (2012).

pubmed: 22286061 doi: 10.1038/nature10833

Xia, L. et al. CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes. Cancer Cell 31, 653–668.e657 (2017).

pubmed: 28486105 pmcid: 5587180 doi: 10.1016/j.ccell.2017.04.005

Clark, J. et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 7, 502–508 (1994).

pubmed: 7951320 doi: 10.1038/ng0894-502

de Leeuw, B., Balemans, M., Olde Weghuis, D. & Geurts van Kessel, A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum. Mol. Genet. 4, 1097–1099 (1995).

pubmed: 7655467 doi: 10.1093/hmg/4.6.1097

Skytting, B. et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J. Natl Cancer Inst. 91, 974–975 (1999).

pubmed: 10359553 doi: 10.1093/jnci/91.11.974

McBride, M. J. et al. The nucleosome acidic patch and H2A ubiquitination underlie mSWI/SNF recruitment in synovial sarcoma. Nat. Struct. Mol. Biol. 27, 836–845 (2020).

pubmed: 32747783 pmcid: 7714695 doi: 10.1038/s41594-020-0466-9

McBride, M. J. et al. The SS18–SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell 33, 1128–1141.e1127 (2018).

pubmed: 29861296 pmcid: 6791822 doi: 10.1016/j.ccell.2018.05.002

Kadoch, C. & Crabtree, G. R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18–SSX oncogenic fusion in synovial sarcoma. Cell 153, 71–85 (2013). These two studies provide an example of how a remodeller may function directly as an oncogene; in this case, by virtue of a genetic translocation in a subunit creating a fusion protein that then drives aberrant remodelling activity.

pubmed: 23540691 pmcid: 3655887 doi: 10.1016/j.cell.2013.02.036

Brien, G. L. et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife 7, e41305 (2018).

pubmed: 30431433 pmcid: 6277197 doi: 10.7554/eLife.41305

Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715–721 (2010).

pubmed: 20601955 pmcid: 2911503 doi: 10.1038/ng.619

Sima, X. et al. The genetic alteration spectrum of the SWI/SNF complex: the oncogenic roles of BRD9 and ACTL6A. PLoS One 14, e0222305 (2019).

pubmed: 31504061 pmcid: 6736241 doi: 10.1371/journal.pone.0222305

Zhao, D. et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542, 484–488 (2017).

pubmed: 28166537 pmcid: 5448706 doi: 10.1038/nature21357

Zhao, D. et al. Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discov. 10, 1374–1387 (2020).

pubmed: 32385075 pmcid: 7483306 doi: 10.1158/2159-8290.CD-19-1352

Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163–178.e119 (2017).

pubmed: 28844694 pmcid: 6791823 doi: 10.1016/j.cell.2017.07.036

The Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438 (2017).

pmcid: 6016744 doi: 10.1038/nature21062

Lelieveld, S. H. et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat. Neurosci. 19, 1194–1196 (2016).

pubmed: 27479843 doi: 10.1038/nn.4352

Rauch, A. et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380, 1674–1682 (2012).

pubmed: 23020937 doi: 10.1016/S0140-6736(12)61480-9

de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921–1929 (2012).

pubmed: 23033978 doi: 10.1056/NEJMoa1206524

Jin, S. C. et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat. Genet. 49, 1593–1601 (2017).

pubmed: 28991257 pmcid: 5675000 doi: 10.1038/ng.3970

Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592–601 (2013). This study extensively surveyed Cancer Genome Atlas data and found that BAF complexes were mutated in almost 20% of all human cancers.

pubmed: 23644491 pmcid: 3667980 doi: 10.1038/ng.2628

Chun, H. E. et al. Genome-wide profiles of extra-cranial malignant rhabdoid tumors reveal heterogeneity and dysregulated developmental pathways. Cancer Cell 29, 394–406 (2016).

pubmed: 26977886 pmcid: 5094835 doi: 10.1016/j.ccell.2016.02.009

George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).

pubmed: 26168399 pmcid: 4861069 doi: 10.1038/nature14664

Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).

pubmed: 23550210 pmcid: 4160307 doi: 10.1126/scisignal.2004088

Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095

Neigeborn, L. & Carlson, M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics 108, 845–858 (1984).

pubmed: 6392017 pmcid: 1224269 doi: 10.1093/genetics/108.4.845

Stern, M., Jensen, R. & Herskowitz, I. Five SWI genes are required for expression of the HO gene in yeast. J. Mol. Biol. 178, 853–868 (1984). These papers discovered SWI/SNF from screens in yeast for defects in sucrose fermentation and pheromone-dependent mating-type switching.

pubmed: 6436497 doi: 10.1016/0022-2836(84)90315-2

Kruger, W. et al. Amino acid substitutions in the structured domains of histones H3 and H4 partially relieve the requirement of the yeast SWI/SNF complex for transcription. Genes. Dev. 9, 2770–2779 (1995).

pubmed: 7590252 doi: 10.1101/gad.9.22.2770

Laurent, B. C., Treich, I. & Carlson, M. Role of yeast SNF and SWI proteins in transcriptional activation. Cold Spring Harb. Symp. Quant. Biol. 58, 257–263 (1993).

pubmed: 7956037 doi: 10.1101/SQB.1993.058.01.030

Laurent, B., Treitel, M. A. & Carlson, M. Functional interdependence of the yeast SNF2, SNF5, and SNF6 proteins in transcriptional activation. Proc. Natl Acad. Sci. USA 88, 2687–2691 (1991).

pubmed: 1901413 pmcid: 51303 doi: 10.1073/pnas.88.7.2687

Peterson, C. L. & Herskowitz, I. Characterization of the yeast SWl, SW2, and SW13 genes, which encode a global activator of transcription. Cell 68, 573–583 (1992).

pubmed: 1339306 doi: 10.1016/0092-8674(92)90192-F

Tamkun, J. W. et al. Brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWl2. Cell 66, 561–572 (1992).

doi: 10.1016/0092-8674(92)90191-E

Kingston, R. E. & Tamkun, J. W. Transcriptional regulation by trithorax-group proteins. Cold Spring Harb. Perspect. Biol. 6, a019349 (2014).

pubmed: 25274705 pmcid: 4176006 doi: 10.1101/cshperspect.a019349

Siebenlist, U. et al. Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol. Cell Biol. 6, 3042–3049 (1986).

pubmed: 3491296 pmcid: 367038

Goldsmith, M. A., Desai, D. M., Schultz, T. & Weiss, A. Function of a heterologous muscarinic receptor in T cell antigen receptor signal transduction mutants. J. Biol. Chem. 264, 17190–17197 (1989).

pubmed: 2529257 doi: 10.1016/S0021-9258(18)71477-4

Socolovsky, M., Dusanter-Fourt, I. & Lodish, H. F. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J. Biol. Chem. 272, 14009–14012 (1997).

pubmed: 9162017 doi: 10.1074/jbc.272.22.14009

Brisken, C., Socolovsky, M., Lodish, H. F. & Weinberg, R. The signaling domain of the erythropoietin receptor rescues prolactin receptor-mutant mammary epithelium. Proc. Natl Acad. Sci. USA 99, 14241–14245 (2002).

pubmed: 12381781 pmcid: 137868 doi: 10.1073/pnas.222549599

Northrop, J. P. et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369, 497–502 (1994).

pubmed: 8202141 doi: 10.1038/369497a0

Khavari, P. A., Peterson, C. L., Tamkun, J. W., Mendel, D. B. & Crabtree, G. R. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature 366, 170–174 (1993).

pubmed: 8232556 doi: 10.1038/366170a0

Muchardt, C. & Yaniv, M. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J. 12, 4279–4290 (1993).

pubmed: 8223438 pmcid: 413724 doi: 10.1002/j.1460-2075.1993.tb06112.x

Stanton, B. Z., Chory, E. J. & Crabtree, G. R. Chemically induced proximity in biology and medicine. Science 359, aa05902 (2018).

doi: 10.1126/science.aao5902

Hathaway, N. A. et al. Dynamics and memory of heterochromatin in living cells. Cell 149, 1447–1460 (2012).

pubmed: 22704655 pmcid: 3422694 doi: 10.1016/j.cell.2012.03.052

Gourisankar, S. et al. Rewiring cancer drivers to activate apoptosis. Nature 620, 417–425 (2023).

pubmed: 37495688 pmcid: 10749586 doi: 10.1038/s41586-023-06348-2

Braun, S. M. G. et al. Rapid and reversible epigenome editing by endogenous chromatin regulators. Nat. Commun. 8, 560 (2017).

pubmed: 28916764 pmcid: 5601922 doi: 10.1038/s41467-017-00644-y

Ren, J., Hathaway, N. A., Crabtree, G. R. & Muegge, K. Tethering of Lsh at the Oct4 locus promotes gene repression associated with epigenetic changes. Epigenetics 13, 173–181 (2017).

doi: 10.1080/15592294.2017.1338234

Marian, C. A. et al. Small molecule targeting of specific BAF (mSWI/SNF) complexes for HIV latency reversal. Cell Chem. Biol. 25, 1443–1455.e1414 (2018).

pubmed: 30197195 pmcid: 6404985 doi: 10.1016/j.chembiol.2018.08.004

Papillon, J. P. N. et al. Discovery of orally active inhibitors of Brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)/SMARCA4-mutant cancers. J. Med. Chem. 61, 10155–10172 (2018).

pubmed: 30339381 doi: 10.1021/acs.jmedchem.8b01318

Chory, E. J. et al. Chemical inhibitors of a selective SWI/SNF function synergize with ATR inhibition in cancer cell killing. ACS Chem. Biol. 15, 1685–1696 (2020).

pubmed: 32369697 pmcid: 8273930 doi: 10.1021/acschembio.0c00312

Kishtagari, A. et al. A first-in-class inhibitor of ISWI-mediated (ATP-dependent) transcription repression releases terminal-differentiation in AML cells while sparing normal hematopoiesis. Blood 132, 216 (2018).

doi: 10.1182/blood-2018-99-119311

Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew. Chem. Int. Edn Engl. 56, 5738–5743 (2017).

doi: 10.1002/anie.201611281

Farnaby, W. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 672–680 (2019).

pubmed: 31178587 pmcid: 6600871 doi: 10.1038/s41589-019-0294-6

Schick, S. et al. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat. Genet. 51, 1399–1410 (2019).

pubmed: 31427792 pmcid: 6952272 doi: 10.1038/s41588-019-0477-9

Rago, F. et al. Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia. Mol. Cancer Res. 20, 361–372 (2022).

pubmed: 34799403 doi: 10.1158/1541-7786.MCR-21-0390

Dann, G. P. et al. ISWI chromatin remodellers sense nucleosome modifications to determine substrate preference. Nature 548, 607–611 (2017).

pubmed: 28767641 pmcid: 5777669 doi: 10.1038/nature23671

Mashtalir, N. et al. Chromatin landscape signals differentially dictate the activities of mSWI/SNF family complexes. Science 373, 306–315 (2021).

pubmed: 34437148 pmcid: 8390793 doi: 10.1126/science.abf8705

Chory, E. J. et al. Nucleosome turnover regulates histone methylation patterns over the genome. Mol. Cell 73, 61–72 e63 (2019).

pubmed: 30472189 doi: 10.1016/j.molcel.2018.10.028

Butler, K. V., Chiarella, A. M., Jin, J. & Hathaway, N. A. Targeted gene repression using novel bifunctional molecules to harness endogenous histone deacetylation activity. ACS Synth. Biol. 7, 38–45 (2018).

pubmed: 29073761 doi: 10.1021/acssynbio.7b00295

Chiarella, A. M. et al. Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery. Nat. Biotechnol. 38, 50–55 (2020).

pubmed: 31712774 doi: 10.1038/s41587-019-0296-7

Abbott, J. M. et al. First-in-class inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer. Mol. Cancer Ther. 19, 1598–1612 (2020).

pubmed: 32499299 pmcid: 7665848 doi: 10.1158/1535-7163.MCT-20-0106

Prigaro, B. J. et al. Design, synthesis, and biological evaluation of the first inhibitors of oncogenic CHD1L. J. Med. Chem. 65, 3943–3961 (2022).

pubmed: 35192363 pmcid: 8981980 doi: 10.1021/acs.jmedchem.1c01778

Vangamudi, B. et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 75, 3865–3878 (2015).

pubmed: 26139243 pmcid: 4755107 doi: 10.1158/0008-5472.CAN-14-3798

Martin, L. J. et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J. Med. Chem. 59, 4462–4475 (2016).

pubmed: 26914985 pmcid: 4885110 doi: 10.1021/acs.jmedchem.5b01865

Remillard, D. et al. Chemoproteomics enabled discovery of selective probes for NuA4 factor BRD8. ACS Chem. Biol. 16, 2185–2192 (2021).

pubmed: 34515462 doi: 10.1021/acschembio.1c00256

Chen, P. et al. Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B. J. Med. Chem. 59, 1410–1424 (2016).

pubmed: 25799074 doi: 10.1021/acs.jmedchem.5b00209

Lu, T. et al. Discovery of high-affinity inhibitors of the BPTF bromodomain. J. Med. Chem. 64, 12075–12088 (2021).

pubmed: 34375106 doi: 10.1021/acs.jmedchem.1c00721

Zahid, H. et al. New design rules for developing potent cell-active inhibitors of the nucleosome remodeling factor (NURF) via BPTF bromodomain inhibition. J. Med. Chem. 64, 13902–13917 (2021).

pubmed: 34515477 pmcid: 9012132 doi: 10.1021/acs.jmedchem.1c01294

Park, S. G., Lee, D., Seo, H. R., Lee, S. A. & Kwon, J. Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells. Sci. Rep. 10, 16330 (2020).

pubmed: 33004947 pmcid: 7529788 doi: 10.1038/s41598-020-73500-7

Shishodia, S. et al. Selective and cell-active PBRM1 bromodomain inhibitors discovered through NMR fragment screening. J. Med. Chem. 65, 13714–13735 (2022).

pubmed: 36227159 pmcid: 9630929 doi: 10.1021/acs.jmedchem.2c00864

Londregan, A. T. et al. Discovery of high-affinity small-molecule binders of the epigenetic reader YEATS4. J. Med. Chem. 66, 460–472 (2023).

pubmed: 36562986 doi: 10.1021/acs.jmedchem.2c01421

Coffey, K. et al. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One 7, e45539 (2012).

pubmed: 23056207 pmcid: 3466219 doi: 10.1371/journal.pone.0045539

Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. 6, a026831 (2016).

pubmed: 27599530 pmcid: 5046688 doi: 10.1101/cshperspect.a026831

Kofink, C. et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat. Commun. 13, 5969 (2022).

pubmed: 36216795 pmcid: 9551036 doi: 10.1038/s41467-022-33430-6

Zoppi, V. et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 62, 699–726 (2019).

pubmed: 30540463 doi: 10.1021/acs.jmedchem.8b01413

Nabet, B. et al. The dTAG system for immediate and target-specific protein degradation. Nat. Chem. Biol. 14, 431–441 (2018).

pubmed: 29581585 pmcid: 6295913 doi: 10.1038/s41589-018-0021-8

Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. Methods 6, 917–922 (2009). These two papers describe two chemical biological tools that use chemically induced proximity to recruit endogenous proteins to the proteosome in order to rapidly delete them in living cells and organisms and have been increasingly deployed to define the direct functions of remodellers.

pubmed: 19915560 doi: 10.1038/nmeth.1401

Context-specific functions of chromatin remodellers in development and disease.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Sai Gourisankar (S)

Andrey Krokhotin (A)

Wendy Wenderski (W)

Gerald R Crabtree (GR)

Classifications MeSH